Eleni Kapsali

Ioannina, ESYE21, Greece

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.

Journal: American journal of hematology
Published: January 30, 2026

Serum Metabolomic Signatures Indicate Oxidative Membrane Lipid Remodeling in β-Thalassemia.

Serum Metabolomic Signatures Indicate Oxidative Membrane Lipid Remodeling in β-Thalassemia.

Journal: Metabolites
Published: January 12, 2026

Decoding Leukemic Stem Cells in AML: From Identification to Targeted Eradication.

Decoding Leukemic Stem Cells in AML: From Identification to Targeted Eradication.

Journal: Diseases (Basel, Switzerland)
Published: December 29, 2025

Applications of Multiparameter Flow Cytometry in the Diagnosis, Prognosis, and Monitoring of Multiple Myeloma Patients.

Applications of Multiparameter Flow Cytometry in the Diagnosis, Prognosis, and Monitoring of Multiple Myeloma Patients.

Journal: Diseases (Basel, Switzerland)
Published: August 08, 2025

Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic Strategies.

Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic Strategies.

Journal: Diseases (Basel, Switzerland)
Published: August 06, 2025

Exportin-1 and epigenetic modifications interaction: more than nuclear transport.

Exportin-1 and epigenetic modifications interaction: more than nuclear transport.

Journal: Human cell
Published: July 26, 2025

Targeting the undruggable MYC in cancer: the rationale of using XPO1 inhibitors.

Targeting the undruggable MYC in cancer: the rationale of using XPO1 inhibitors.

Journal: Molecular biology reports
Published: February 27, 2025

The Prognostic Impact of Additional Molecular and Cytogenetic Abnormalities on AML Patients with NPM1- and/or FLT3-ITD Mutations Receiving Intensive Chemotherapy: Real-World Data from the Greek Registry.

The Prognostic Impact of Additional Molecular and Cytogenetic Abnormalities on AML Patients with NPM1- and/or FLT3-ITD Mutations Receiving Intensive Chemotherapy: Real-World Data from the Greek Registry.

Journal: Cancers
Published: January 02, 2025

Comparative analysis of mortality patterns and treatment strategies in thalassaemia and sickle cell disease patients: A 12-year study.

Comparative analysis of mortality patterns and treatment strategies in thalassaemia and sickle cell disease patients: A 12-year study.

Journal: British journal of haematology
Published: December 03, 2024

The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi-center analysis of 719 disease episodes.

The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi-center analysis of 719 disease episodes.

Journal: American journal of hematology
Published: June 07, 2024

Imaging Flow Cytometry: Development, Present Applications, and Future Challenges.

Imaging Flow Cytometry: Development, Present Applications, and Future Challenges.

Journal: Methods and protocols
Published: January 29, 2024

Central Diabetes Insipidus in a Patient With Lymphoma: A Case Report.

Central Diabetes Insipidus in a Patient With Lymphoma: A Case Report.

Journal: Cureus
Published: July 07, 2023
Showing 1-12 of 28

Last Updated: 09/26/2026